ASHP statement on the over-the-counter availability of statins

American Journal of Health-System Pharmacy

Volumn 62, Issue 22, 2005, Pages 2420-2422

[No Author Info available]

Author keywords

American Society of Health System Pharmacists; Antilipemic agents; Classification; Coronary disease; Dispensing; Drugs, noriprescription; Hyperlipidemia; Models; Protocols; Regulations; Toxicity

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NON PRESCRIPTION DRUG; SIMVASTATIN; STATINE DERIVATIVE;

ARTICLE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DYSLIPIDEMIA; HEALTH CARE ORGANIZATION; ISCHEMIC HEART DISEASE; MODEL; PHARMACIST; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION;

EID: 28244488194     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050342     Document Type: Article

References (9)

1. Policy position 0220: intermediate category of drugs. In: Hawkins B, ed. Best practices for hospital and health-system pharmacy, position and guidance documents of ASHP. 2004-2005 ed. Bethesda, MD: American Society of Health-System Pharmacists; 2004:89.
2. American Society of Health-System Pharmacists. ASHP therapeutic position statement on the use of statins in the prevention of atherosclerotic disease in adults. Am J Health-Syst Pharm. 2003; 60:593-8.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-97.
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106:3143-421.
5. American Heart Association. 2002 heart and stroke statistical update, http://circ.ahajournals.org/cgi/content/full/106/25/3140 (accessed 2002 May 14).
6. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110:227-39.
7. Food and Drug Administration. Questions to the committee to consider new drug application 21-213. www.fda.gov/ohrms/dockets/ac/05/questions/2005- 4086S2_02_FDA-Questions.htm (accessed 2005 Jan 26).
8. Melin JM, Struble WE, Tipping RW et al. A consumer use study of over-the-counter lovastatin (CUSTOM). Am J Cardiol. 2004; 94:1243-8.
9. Royal Pharmaceutical Society of Great Britain. Practice guidance: OTC simvastatin (concise version). July 2004. www.rpsgb.org/pdfs/ otcsimvastatincardguid.pdf (accessed 2005 Jan 4).